Contributions
Abstract: P271
Type: Poster
Abstract Category: Clinical aspects of MS - MS Variants
Objective: To evaluate the clinical features of patients with Neuromyelitis optica (NMO) diagnosed by Wingerchuck 2006 criteria (who also fulfilled new IPND criteria), who were seronegative for both anti-MOG and anti-AQP4 antibody (Ab).
Methods: In this multicentre collaboration (India, Brazil, Thailand and Japan), sera of 190 consecutive NMO patients were tested by CBA at Tohoku University,Japan for Anti-AQP4 and anti-MOG antibody using live transfected cells with AQP4-M23 or full-length MOG.
Results: Among them 34 (17.9%) patients were seronegative for both anti-MOG and anti-AQP4 Ab and all had a relapsing disease course. There were 20 women and 14 men who had the first attack at a median age of 26 (8-56) years. The initial attack was located in the spinal cord in 74.3%. During a follow up of 7.0 years (range 1-38), attack frequency was 3 (1- 18) and last EDSS 4.3 (0-10). Severe visual loss (VA < 20/200) was seen in 20.6%. Bilateral optic neuritis (20.6%), simultaneous myelitis and ON (5.8%) and area postrema syndrome (14.7%) were less common than reported in anti-AQP4+ patients. MRI of the spinal cord showed longitudinally extensive myelitis in cervical/dorsal (45.7%) and dorsal (34.3%) regions of the cord. Brain MRI was abnormal in 68.5% and most often showed atypical subcortical white matter lesions. Overall they were treated with corticosteroids and/or immunosuppressants.
Conclusions: Seronegative NMO had a relapsing course, no gender predilection, and relatively early onset of disease. Relapsing disease may require the initiation of long-term immunosuppression.
Disclosure:
Pandit L: nothing to disclose
Sato D: nothing to disclose
Siritho S: nothing to disclose
Nakashima I: nothing to disclose
Kaneko K: nothing to disclose
Morale V: nothing to disclose
Callegaro D: nothing to disclose
Rodrigues dos Passos G: nothing to disclose
Becker J: nothing to disclose
Fujihara K: nothing to disclose
Abstract: P271
Type: Poster
Abstract Category: Clinical aspects of MS - MS Variants
Objective: To evaluate the clinical features of patients with Neuromyelitis optica (NMO) diagnosed by Wingerchuck 2006 criteria (who also fulfilled new IPND criteria), who were seronegative for both anti-MOG and anti-AQP4 antibody (Ab).
Methods: In this multicentre collaboration (India, Brazil, Thailand and Japan), sera of 190 consecutive NMO patients were tested by CBA at Tohoku University,Japan for Anti-AQP4 and anti-MOG antibody using live transfected cells with AQP4-M23 or full-length MOG.
Results: Among them 34 (17.9%) patients were seronegative for both anti-MOG and anti-AQP4 Ab and all had a relapsing disease course. There were 20 women and 14 men who had the first attack at a median age of 26 (8-56) years. The initial attack was located in the spinal cord in 74.3%. During a follow up of 7.0 years (range 1-38), attack frequency was 3 (1- 18) and last EDSS 4.3 (0-10). Severe visual loss (VA < 20/200) was seen in 20.6%. Bilateral optic neuritis (20.6%), simultaneous myelitis and ON (5.8%) and area postrema syndrome (14.7%) were less common than reported in anti-AQP4+ patients. MRI of the spinal cord showed longitudinally extensive myelitis in cervical/dorsal (45.7%) and dorsal (34.3%) regions of the cord. Brain MRI was abnormal in 68.5% and most often showed atypical subcortical white matter lesions. Overall they were treated with corticosteroids and/or immunosuppressants.
Conclusions: Seronegative NMO had a relapsing course, no gender predilection, and relatively early onset of disease. Relapsing disease may require the initiation of long-term immunosuppression.
Disclosure:
Pandit L: nothing to disclose
Sato D: nothing to disclose
Siritho S: nothing to disclose
Nakashima I: nothing to disclose
Kaneko K: nothing to disclose
Morale V: nothing to disclose
Callegaro D: nothing to disclose
Rodrigues dos Passos G: nothing to disclose
Becker J: nothing to disclose
Fujihara K: nothing to disclose